APA (7th ed.) Citation

R, D., P, D., N, S., A, S., & A, A. (2026). Cucurbitacin derivatives (B, IIa, IIb, and E): Modulating gut dysbiosis and inflammatory pathways for multi-target therapy of ulcerative colitis. Inflammopharmacology, 34(7), 4463. https://doi.org/10.1007/s10787-026-02284-5

Chicago Style (17th ed.) Citation

R, Devi, Dadwal P, Sharma N, Singh A, and Arora A. "Cucurbitacin Derivatives (B, IIa, IIb, and E): Modulating Gut Dysbiosis and Inflammatory Pathways for Multi-target Therapy of Ulcerative Colitis." Inflammopharmacology 34, no. 7 (2026): 4463. https://doi.org/10.1007/s10787-026-02284-5.

MLA (9th ed.) Citation

R, Devi, et al. "Cucurbitacin Derivatives (B, IIa, IIb, and E): Modulating Gut Dysbiosis and Inflammatory Pathways for Multi-target Therapy of Ulcerative Colitis." Inflammopharmacology, vol. 34, no. 7, 2026, p. 4463, https://doi.org/10.1007/s10787-026-02284-5.